Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase II Trial of PRT-064040 Nasal Spray for the Acute Treatment of Migraine
Latest Information Update: 10 Feb 2026
At a glance
- Drugs PRT 064040 (Primary)
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Therapeutic Use
- Sponsors Sichuan Purity Pharmaceutical Technology
Most Recent Events
- 29 Jan 2026 Status changed from not yet recruiting to recruiting.
- 30 Dec 2025 New trial record